Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Clin Oral Investig ; 23(1): 161-167, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29654563

RESUMO

OBJECTIVES: To investigate teeth's antibiotic-induced color differences after bleaching using two different techniques. MATERIALS AND METHODS: One hundred twenty extracted maxillar human incisors were examined. The specimens were randomly divided into six groups, each receiving one of six antibiotic paste fillings: (1) triple antibiotic paste (TAP) with minocycline, (2) double antibiotic paste (DAP), (3) TAP with amoxicillin, (4) TAP with cefaclor, (5) TAP with doxycycline, and (6) no filling (control group). Spectrophotometric measurements were obtained at baseline and then during the first, second, and third weeks after paste placement. The specimens discolored by antibiotics pastes were randomly divided into two subgroups: (1) internal bleaching with hydrogen peroxide (H2O2) and (2) internal bleaching with H2O2 plus Nd-YAG laser irradiation. The ∆E value was calculated and analyzed using a two-way analysis of variance and post-hoc Tukey's test (α = 0.05). RESULTS: The ∆E for all groups showed color differences exceeding the perceptibility threshold (∆E Ëƒ 3.7) at all time points except in the control and DAP groups. Minocycline-induced TAP showed the most severe coronal discoloration (32.42). When the ∆E was examined, thermo/photo bleaching (22.01 ± 8.23) caused more bleaching than walking bleaching (19.73 ± 5.73) at every time point (P = 0.19). No group returned to the original color after bleaching (P < 0.05). CONCLUSIONS: Except for DAP, all antibiotic pastes caused discoloration. Internal bleaching with Nd-YAG laser can be useful for bleaching/removing this discoloration. CLINICAL RELEVANCE: For clinically successful final appearances, understanding the effects of bleaching procedures on antibiotic paste discoloration is important.


Assuntos
Antibacterianos/efeitos adversos , Lasers de Estado Sólido/uso terapêutico , Espectrofotometria/métodos , Clareamento Dental/métodos , Descoloração de Dente/induzido quimicamente , Descoloração de Dente/terapia , Amoxicilina/efeitos adversos , Amoxicilina/uso terapêutico , Antibacterianos/uso terapêutico , Cefaclor/efeitos adversos , Cefaclor/uso terapêutico , Ciprofloxacina/efeitos adversos , Ciprofloxacina/uso terapêutico , Doxiciclina/efeitos adversos , Doxiciclina/uso terapêutico , Humanos , Peróxido de Hidrogênio/uso terapêutico , Técnicas In Vitro , Metronidazol/efeitos adversos , Metronidazol/uso terapêutico , Minociclina/efeitos adversos , Minociclina/uso terapêutico
2.
Ann Ital Chir ; 95(3): 374-381, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38918968

RESUMO

AIM: Chronic periodontitis leads to gingival swelling, hyperplasia, and tooth mobility, which affects orthodontic treatment. The aim of this study was to investigate the application of cefaclor in orthodontics through micro-implant anchorage in patients with periodontitis. METHODS: A retrospective study was conducted on patients with periodontitis who received micro-implant anchorage treatment in the department of orthodontics at the First People's Hospital of Yongkang City from July 2019 to January 2022. According to different treatment regimens, these patients were divided into the test group (patients receiving cefaclor and micro-implant anchorage treatment) and the control group (patients receiving micro-implant anchorage treatment only). The plaque index (PLI), gingival index (GI), sulcus bleeding index (SBI), and serum inflammatory factor levels were compared between the two groups after treatment. RESULTS: One hundred and five patients were included in the study, (44 males and 61 females, median age 21 [15-25] years), 51 in the cefaclor group and 54 in the no cefaclor group. After treatment, the PLI, GI, and SBI scores in the two groups were higher than those before treatment, and the levels of serum inflammatory markers significantly increased (p < 0.05). After treatment, the PLI, GI, and SBI scores in the test group were significantly lower than those in the control group (p < 0.001). The levels of serum interleukin-1ß, interleukin-6, interleukin-8, and tumor necrosis factor-α were significantly lower in the test group, and the interleukin-2 level was higher in the test group (p < 0.001). There was no significant difference in the incidence of complications between the two groups (p > 0.05). CONCLUSIONS: Cefaclor and micro-implant anchorage have a good clinical effect on orthodontics in patients with periodontitis, improving periodontal health and reducing inflammatory response.


Assuntos
Cefaclor , Humanos , Feminino , Masculino , Estudos Retrospectivos , Adulto , Cefaclor/uso terapêutico , Adulto Jovem , Adolescente , Antibacterianos/uso terapêutico , Procedimentos de Ancoragem Ortodôntica , Índice Periodontal , Periodontite Crônica/complicações , Periodontite Crônica/terapia , Periodontite Crônica/tratamento farmacológico , Periodontite Crônica/sangue , Implantes Dentários
3.
Assay Drug Dev Technol ; 19(3): 156-175, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33728979

RESUMO

Corona virus disease-2019 (COVID-19) emerged in Wuhan, China in December 2019 and was declared as a pandemic by the World Health Organization in March 2020. Although there is no complete treatment protocol for COVID-19, studies on this topic are ongoing, and it is known that broad-spectrum antibiotics such as cephalosporins are used for coinfections and symptoms in COVID-19 patients. Studies have shown that Staphylococcus aureus and Escherichia coli bacteria can cause symptoms such as diarrhea and coinfections accompanying COVID-19. Therefore, in this study, colon-targeted cefaclor monohydrate (CEF)-loaded poly(lactic-co-glycolic acid) (PLGA)-Eudragit S100 nanoparticles (NPs) were prepared using a nanoprecipitation technique. The particle sizes of the CEF-loaded NPs were between 171.4 and 198.8 nm. The encapsulation efficiency was in the range of 58.4%-81.2%. With dissolution studies, it has been concluded that formulations prepared with Eudragit S100 (E-coded) and Eudragit S100+PLGA (EP-coded) are pH-sensitive formulations and they are targetable to the colon, whereas the formulation prepared only with PLGA (P-coded) can release a higher CEF rate in the colon owing to the slow release properties of PLGA. The release kinetics were fitted to the Korsmeyer-Peppas and Weibull models. The antibacterial activity of E-, EP-, and P-coded formulations was 16-fold, 16-fold, and 2-fold higher than CEF, respectively, for S. aureus and E. coli according to the microdilution results. As a result of the time killing experiment, all formulations prepared were found to be more effective than the antibiotic itself for long periods. Consequently, all formulations prepared in this study hope to guide researchers/clinicians in treating both gram-positive and gram-negative bacteria-induced infections, as well as COVID-19 associated coinfections and symptoms.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Infecções Bacterianas/complicações , Infecções Bacterianas/tratamento farmacológico , COVID-19/complicações , Cefaclor/administração & dosagem , Cefaclor/uso terapêutico , Enteropatias/complicações , Enteropatias/tratamento farmacológico , Antibacterianos/farmacologia , Cefaclor/farmacologia , Coinfecção , Composição de Medicamentos , Escherichia coli/efeitos dos fármacos , Excipientes , Cinética , Testes de Sensibilidade Microbiana , Nanopartículas , Tamanho da Partícula , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Ácidos Polimetacrílicos , Staphylococcus aureus/efeitos dos fármacos
4.
Pediatr Dent ; 29(1): 47-50, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-18041512

RESUMO

The purpose of this report was to present the case of a patient wherein revascularization of the necrotic infected pulp space of an immature permanent maxillary central incisor tooth was induced in vivo by stimulation of a blood clot from the periapical tissues into the canal space. This was achieved after disinfection of the canal space with a topical antibiotic paste followed by a blood clot scaffold induced from the periapical tissues. This treatment approach offers clinicians great potential to avoid the need for traditional apexification with calcium hydroxide or the need to achieve an artificial apical barrier with mineral trioxide aggregate. Furthermore, this treatment approach can help rescue infected immature teeth by physiologically strengthening the root walls.


Assuntos
Necrose da Polpa Dentária/terapia , Polpa Dentária/irrigação sanguínea , Incisivo/fisiopatologia , Odontogênese/fisiologia , Compostos de Alumínio/uso terapêutico , Antibacterianos/uso terapêutico , Anti-Infecciosos/uso terapêutico , Coagulação Sanguínea/fisiologia , Compostos de Cálcio/uso terapêutico , Cefaclor/uso terapêutico , Criança , Polpa Dentária/fisiopatologia , Cavidade Pulpar/fisiopatologia , Desinfetantes/uso terapêutico , Desinfecção/métodos , Combinação de Medicamentos , Seguimentos , Humanos , Masculino , Metronidazol/uso terapêutico , Óxidos/uso terapêutico , Tecido Periapical/fisiopatologia , Povidona-Iodo/uso terapêutico , Materiais Restauradores do Canal Radicular/uso terapêutico , Silicatos/uso terapêutico , Hipoclorito de Sódio/uso terapêutico , Ápice Dentário/fisiopatologia
5.
J Dermatol ; 22(10): 804-6, 1995 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8586766

RESUMO

We report a case of cheilitis granulomatosa with periodontitis in a 39-year-old Japanese man. Biopsy specimens from both areas showed noncaseating epithelioid cell granuloma. Dental examination revealed that the lower left first molar had periodontitis. The lower left first molar was removed, and antibiotics and anti-inflammatory drugs were administered. After 2 months of periodontitis therapy, the lips returned to normal size without recurrence and the swelling of the buccal mucosa regressed.


Assuntos
Síndrome de Melkersson-Rosenthal/complicações , Periodontite/complicações , Adulto , Anti-Inflamatórios/uso terapêutico , Cefaclor/uso terapêutico , Cefalosporinas/uso terapêutico , Humanos , Masculino , Síndrome de Melkersson-Rosenthal/patologia , Síndrome de Melkersson-Rosenthal/terapia , Dente Molar , Periodontite/patologia , Periodontite/terapia , Extração Dentária
6.
Artigo em Inglês | MEDLINE | ID: mdl-11402275

RESUMO

OBJECTIVE: The purpose of this study was to evaluate various oral antimicrobial agent levels in tooth extraction sites. STUDY DESIGN: The concentration of dental alveolar blood in extraction wounds after the oral administration of talampicillin (500 mg), cefaclor (500 mg), cefteram pivoxil (200 mg), cefuroxime axetil (250 mg), cefdinir (200 mg), and ofloxacin (100 mg) was determined in 338 patients and was assessed on the basis of its antimicrobial activity against Streptococcus isolated in odontogenic infections. RESULTS: The percentage of patients whose concentrations exceeded the minimum inhibitory concentration for 90% of Streptococcus was 62.5% to 100% for talampicillin at 30 to 360 minutes, 0% to 12.5% for cefaclor at 30 to 360 minutes, 18.2% to 100% for cefteram pivoxil at 30 to 480 minutes, 50% to 100% for cefuroxime axetil at 30 to 480 minutes, 0% to 50% for cefdinir at 16 to 290 minutes, and 0% to 40% for ofloxacin at 30 to 480 minutes. CONCLUSION: These results indicate that talampicillin, cefteram pivoxil, and cefuroxime axetil have minimum inhibitory concentration levels for 90% of Streptococcus in tooth sockets.


Assuntos
Antibacterianos/sangue , Cefmenoxima/análogos & derivados , Extração Dentária , Administração Oral , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Processo Alveolar/metabolismo , Antibacterianos/uso terapêutico , Cefaclor/sangue , Cefaclor/uso terapêutico , Cefdinir , Cefmenoxima/sangue , Cefmenoxima/uso terapêutico , Cefuroxima/análogos & derivados , Cefuroxima/sangue , Cefuroxima/uso terapêutico , Cefalosporinas/sangue , Cefalosporinas/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ofloxacino/sangue , Ofloxacino/uso terapêutico , Penicilinas/sangue , Penicilinas/uso terapêutico , Pró-Fármacos/análise , Pró-Fármacos/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Streptococcus/efeitos dos fármacos , Talampicilina/sangue , Talampicilina/uso terapêutico , Fatores de Tempo , Doenças Dentárias/tratamento farmacológico , Doenças Dentárias/microbiologia , Alvéolo Dental/metabolismo
7.
Jpn J Antibiot ; 37(1): 152-75, 1984 Jan.
Artigo em Japonês | MEDLINE | ID: mdl-6374193

RESUMO

A comparative clinical study of cefaclor (CCL) with cephalexin (CEX) was carried out by randomized double-blind techniques in order to contemplate the clinical efficacy, side effects and usefulness in treatment of 243 patients with dental infections. In the CEX group, CEX was orally administered 4 times a day at a daily dosage of 1,000 mg for 3 to 5 days. In the CCL group, CCL was orally administered 3 times a day at a daily dosage of 750 mg for 3 to 5 days and 1 capsule of placebo was also given every evening in order to keep the blindness of the administration. Evaluable cases for efficacy of athe drugs were 213 consisting of 108 for CCL and 105 for CEX. There were no significant differences in background of the patients and severity of the disease between 2 treatment groups. Clinical effectiveness on the 3rd day was 89.7% in CCL group and 78.6% in CEX group, showing significant difference between 2 treatment groups. Clinical effectiveness on the final day of administration was 94.4% in CCL group and 92.4% in CEX group, showing no significant difference between 2 treatment groups. Side effects were found in 10.5% of 114 patients receiving CCL and in 4.5% of 112 patients with CEX, and there was no significant difference between 2 treatment groups. The side effects were mostly gastrointestinal origin. According to the judgement by physicians in charge, no significant difference was seen in clinical usefulness between the 2 drugs.


Assuntos
Infecções Bacterianas/tratamento farmacológico , Cefaclor/uso terapêutico , Cefalexina/análogos & derivados , Cefalexina/uso terapêutico , Doenças Maxilomandibulares/tratamento farmacológico , Periodontite/tratamento farmacológico , Adulto , Idoso , Cefaclor/administração & dosagem , Cefalexina/administração & dosagem , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
8.
Jpn J Antibiot ; 38(4): 1117-40, 1985 Apr.
Artigo em Japonês | MEDLINE | ID: mdl-3897614

RESUMO

In vitro viable cell count studies of sustained release preparations of cefaclor (CCL) conclude that the mixture of nonenteric and enteric coated granules of CCL in the ratio of 4 to 6 is the most appropriate form (4:6 form) for the sustained release preparation of CCL. In order to clinically confirm the above conclusion, comparative double blind clinical studies of 3 mixtures forms (2:8, 4:6 and 6:4 forms) with a regular preparation (CCL form) were conducted in dental infections regarding efficacy, safety, and usefulness of the 4 forms. Evaluable cases for efficacy and usefulness were 364 in total (96 cases for the 2:8 form group, 89 cases for the 4:6 form group, 89 cases for the 6:4 form group, and 90 cases for the CCL form group). Evaluable cases for safety were 404 cases in total (102 for the 2:8 form, 100 for the 4:6 form, 102 for the 6:4 form, and 100 for the CCL form). Daily dose of the 3 forms of sustained release preparations was 375 mg b.i.d. after breakfast and dinner and that of the CCL form 250 mg t.i.d. after breakfast, lunch and dinner. Following are the results of the clinical studies: There were no significant differences among the 4 patient-groups (2:8 form, 4:6 form, 6:4 form, and CCL form) regarding background factors of the patients and findings of their subjective and objective symptoms before the initiation of the administration, and it was therefore confirmed that there were no problems in conducting the comparative double blind clinical studies. Overall clinical effective rate determined by the efficacy evaluation criteria of the Japanese society of oral surgery (JSOS) were 89.5% at day 3 and 94.8% at day 5 in the 2:8 form group, 87.4% at day 3 and 95.5% at day 5 in the 4:6 form group, 86.4% at day 3 and 91.0% at day 5 in the 6:4 form group, and 93.3% at day 3 and 96.7% at day 5 in the CCL form group. The effective rate determined by the physicians who actually treated the patients were 84.4% in the 2:8 form group, 87.6% in the 4:6 form group, 84.1% in the 6:4 form group, and 87.8% in the CCL form group. In both judgments by the efficacy evaluation criteria of JSOS and the physicians, there were no significant differences among the 4 forms regarding overall clinical efficacy.(ABSTRACT TRUNCATED AT 400 WORDS)


Assuntos
Infecções Bacterianas/tratamento farmacológico , Cefaclor/administração & dosagem , Cefalexina/análogos & derivados , Doenças da Boca/tratamento farmacológico , Adolescente , Adulto , Idoso , Cefaclor/efeitos adversos , Cefaclor/uso terapêutico , Ensaios Clínicos como Assunto , Preparações de Ação Retardada , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
9.
Jpn J Antibiot ; 37(6): 1006-22, 1984 Jun.
Artigo em Japonês | MEDLINE | ID: mdl-6387212

RESUMO

Fundamental and clinical studies on cefaclor (CCL) have been performed and the following results were obtained. CCL was orally administered to NZW rabbits at the dose of 20 mg/kg, and its concentrations in blood and various tissues of oral organs were determined. Pattern of change in its blood concentration after the administration was similar to that of change in its concentration in the tissues of oral organs. Its concentration in blood was the highest followed by gingiva, parotid gland, submandibular gland, cervical lymph node and tongue in descending order. Comparative studies of CCL against cephalexin (CEX) were conducted in 5 healthy volunteers with cross over method. The 5 volunteers were orally given 500 mg of CCL or CEX at 1 dose after meal. Peak blood levels of CCL and CEX were 14.8 micrograms/ml at 2 hours and 11.5 micrograms/ml at 3 hours, respectively. The dose of 750 or 1,500 mg/day of CCL in 3 divided doses was orally administered to 71 patients with acute purulent infections in oral tissues for 3 to 13 days. Evaluation of effect was determined by the criteria for evaluation of antimicrobial agents in oral surgery. Out of the 70 patients, excellent clinical response was observed in 18 patients, good in 40, and poor in 12. Effective rate was 83%. In vitro antibacterial activities (MIC) of CCL and CEX were studied in 74 out of 81 strains (41 from aerobes and 40 from anaerobes) isolated from 47 patients. CCL showed stronger antibacterial activities than CEX. MICs of CCL against 30 strains of Gram-positive anaerobes were distributed from 0.10 to 3.13 micrograms/ml with a peak of 0.78 micrograms/ml. As adverse reaction due to CCL, eruption was observed in only 1 patient. Laboratory tests in 61 patients who received CCL showed elevation of GOT in 1 patient and elevation of GOT and GPT in 1 patient. From the above fundamental and clinical results, CCL was considered to be a useful antibiotic for the treatment of acute purulent infections caused by aerobes and anaerobes in oral surgery field.


Assuntos
Cefaclor/uso terapêutico , Cefalexina/análogos & derivados , Periodontite/tratamento farmacológico , Adolescente , Adulto , Idoso , Animais , Cefaclor/sangue , Criança , Feminino , Gengiva/análise , Humanos , Doenças Maxilomandibulares/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Periodontite/sangue , Coelhos , Streptococcus pyogenes/efeitos dos fármacos , Glândula Submandibular/análise
10.
Jpn J Antibiot ; 37(3): 318-28, 1984 Mar.
Artigo em Japonês | MEDLINE | ID: mdl-6737694

RESUMO

Cefaclor (CCL) is a cephem antibiotic for oral use. Thirty cases of infection of oral regions, in the First Department of Oral and Maxillofacial Surgery, School of Dentistry, the University of Tokushima, were treated with CCL at 750 mg/day. The results were as follows: The efficacy rate for all kinds of diseases was 80.0% in 3 days and 96.7% in 5 days and 86.7% as an overall assessment by the patients' doctors. With regard to the degree of symptoms, the efficacy rate for cases with moderate symptoms was less than that for mild cases in 3 days and according to the assessment by the patients' doctors. Some moderate cases required increased medication because no beneficial effect was observed. In sensitivity tests, CCL was shown to be effective on all 27 isolated clones of bacteria tested. CCL caused no detectable changes in laboratory data. No side effects were observed in any case. From these results, it is concluded that CCL is a highly effective antibiotic for use on infections of the oral regions.


Assuntos
Infecções Bacterianas/tratamento farmacológico , Cefaclor/uso terapêutico , Cefalexina/análogos & derivados , Doenças da Boca/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Idoso , Bactérias/efeitos dos fármacos , Bactérias/isolamento & purificação , Infecções Bacterianas/microbiologia , Cefaclor/administração & dosagem , Cefaclor/farmacologia , Avaliação de Medicamentos , Resistência Microbiana a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doenças da Boca/microbiologia
11.
Jpn J Antibiot ; 43(12): 2035-68, 1990 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-2086820

RESUMO

To evaluate objectively clinical efficacy, safety and usefulness of cefuroxime axetil (CXM-AX) in acute dental infections (periodontitis, pericoronitis and gnathitis), we carried out a comparison study using cefaclor (CCL) as the control. Both drugs were orally given after meals in a dose level of 250 mg (potency) t.i.d. for 3-7 days. 1. Clinical efficacy rates in all the treated cases were 81.6% (102/125) in the CXM-AX group and 82.5% (104/126) in the CCL group according to the assessment by physicians in charge, and 89.6% (112/125) and 83.3% (105/126), respectively, according to the assessment based on scores. No significant difference was found between the 2 treatment groups. In clinical efficacy (assessment by score) classified by background factors, efficacy rate in the CXM-AX group (90.6%, 58/64) was significantly higher (P less than 0.05) than that in the CCL group (75.0%, 48/64) in cases receiving no surgical treatment on the first day of drug administration. Other background factors than the above (no surgical treatment) factor or scores on the first day of drug administration, however, did not appear to influence clinical efficacies of 2 treatment groups. 2. As for the bacteriological response in all the treated cases, elimination rate in the CXM-AX group was 73.7% (28/38) and that in the CCL group, 78.3% (36/46), without significant difference between the 2 groups. 3. Regarding the safety, no significant difference was found between the 2 treatment groups. Adverse reactions were observed in 1 out of 128 cases (0.8%) in the CXM-AX group and 6 out of 132 cases (4.5%) in the CCL group. Abnormal laboratory test values were noted in 8 out of 86 cases (9.3%) in the CXM-AX group and 5 out of 91 cases (5.5%) in the CCL group. None of these differences between 2 treatment groups was statistically significant. 4. Usefulness rates in all the treated cases were 81.6% (102/125) in the CXM-AX group and 81.7% (103/126) in the CCL group, thus significant difference was observed between the 2 groups. From the above results, CXM-AX is considered to be a useful drug like CCL in the treatment of acute dental infections.


Assuntos
Infecções Bacterianas , Cefuroxima/análogos & derivados , Doenças Maxilomandibulares/tratamento farmacológico , Pericoronite/tratamento farmacológico , Periodontite/tratamento farmacológico , Pró-Fármacos/uso terapêutico , Doença Aguda , Adolescente , Adulto , Idoso , Bactérias/efeitos dos fármacos , Bactérias/isolamento & purificação , Cefaclor/efeitos adversos , Cefaclor/farmacologia , Cefaclor/uso terapêutico , Cefuroxima/efeitos adversos , Cefuroxima/farmacologia , Cefuroxima/uso terapêutico , Método Duplo-Cego , Resistência Microbiana a Medicamentos , Feminino , Humanos , Doenças Maxilomandibulares/microbiologia , Masculino , Pessoa de Meia-Idade , Pericoronite/microbiologia , Periodontite/microbiologia , Pró-Fármacos/efeitos adversos , Pró-Fármacos/farmacologia
12.
J Endod ; 40(6): 845-8, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24862714

RESUMO

INTRODUCTION: Antibiotic pastes are used for disinfection in regenerative endodontic procedures. This study evaluated the crown discoloration induced by various antibiotic pastes including the mixture of metronidazole and ciprofloxacin with minocycline, doxycycline, amoxicillin, or cefaclor. METHODS: Seventy extracted bovine incisors were sectioned to obtain a standardized root length of 10 mm above the facial cementoenamel junction. After pulp tissue removal, irrigation with sodium hypochlorite and the placement of temporary filling material and cotton pellet were performed from the apical aspect. The specimens were then randomly divided into 7 groups (n = 10 for each group), and each group received the following antibiotic paste fillings: no filling (control group), calcium hydroxide, double antibiotic paste (DAP), triple antibiotic paste (TAP) with minocycline, TAP with doxycycline, TAP with amoxicillin, and TAP with cefaclor. Spectrophotometric readings were obtained on the buccal surfaces of the crown on day 1 to week 3 after filling, and the ΔE value was calculated. Data were analyzed with 2-way analysis of variance and the Tukey post hoc tests (P = .05), and the human perceptibility threshold was set to 3.7. RESULTS: TAP with minocycline, doxycycline, and cefaclor induced more coronal discoloration compared with the control group (P < .05). The control, calcium hydroxide, and DAP groups showed no color changes exceeding the perceptibility threshold at all time points. CONCLUSIONS: The results indicated that all antibiotic pastes, except DAP, induced crown discoloration.


Assuntos
Antibacterianos/efeitos adversos , Tratamento do Canal Radicular/métodos , Coroa do Dente/patologia , Descoloração de Dente/patologia , Amoxicilina/efeitos adversos , Amoxicilina/uso terapêutico , Animais , Hidróxido de Cálcio/uso terapêutico , Bovinos , Cefaclor/efeitos adversos , Cefaclor/uso terapêutico , Ciprofloxacina/efeitos adversos , Ciprofloxacina/uso terapêutico , Percepção de Cores , Doxiciclina/efeitos adversos , Doxiciclina/uso terapêutico , Metronidazol/efeitos adversos , Metronidazol/uso terapêutico , Distribuição Aleatória , Regeneração , Materiais Restauradores do Canal Radicular/uso terapêutico , Irrigantes do Canal Radicular/uso terapêutico , Preparo de Canal Radicular/métodos , Hipoclorito de Sódio/uso terapêutico , Espectrofotometria/métodos , Fatores de Tempo , Descoloração de Dente/induzido quimicamente
13.
Pediatr Dent ; 34(5): 414-7, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23211919

RESUMO

The purpose of this case series was to report on the use of a technique of revascularization for necrotic immature permanent teeth, several problems encountered, and solutions to those problems. Eighteen pulp revascularizations were performed in 2009 using the original protocol of revascularization (adapted from the AAE/AAPD joint meeting in 2007 in Chicago). The protocol consisted of opening the canal and disinfecting it with sodium hypochlorite, sealing in a triple antibiotic paste for 2-6 weeks, re-opening, re-irrigating, creating a blood clot in the canal, and sealing with an MTA barrier over the clot. Three problems were encountered during the treatment: (1) bluish discoloration of the crown; (2) failure to produce bleeding; and (3) collapse of the mineral trioxide aggregate (MTA) material into the canal. Modifications to solve these problems included: changing one of the antibiotics, using a local anesthesia without epinephrine, and adding collagen matrix to the blood clot.


Assuntos
Coagulação Sanguínea/fisiologia , Necrose da Polpa Dentária/terapia , Polpa Dentária/irrigação sanguínea , Neovascularização Fisiológica , Tratamento do Canal Radicular/efeitos adversos , Tratamento do Canal Radicular/métodos , Descoloração de Dente/induzido quimicamente , Adolescente , Compostos de Alumínio/efeitos adversos , Antibacterianos/efeitos adversos , Antibacterianos/uso terapêutico , Apexificação/métodos , Compostos de Cálcio/efeitos adversos , Cefaclor/uso terapêutico , Criança , Colágeno/uso terapêutico , Necrose da Polpa Dentária/etiologia , Dentição Permanente , Combinação de Medicamentos , Epinefrina/efeitos adversos , Humanos , Minociclina/efeitos adversos , Óxidos/efeitos adversos , Materiais Restauradores do Canal Radicular/efeitos adversos , Irrigantes do Canal Radicular/uso terapêutico , Silicatos/efeitos adversos , Hipoclorito de Sódio/uso terapêutico , Traumatismos Dentários/complicações , Vasoconstritores/efeitos adversos
16.
J Endod ; 34(12): 1451-6, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19026872

RESUMO

This study assessed the prevalence and microbial interactions of Fusobacterium nucleatum and Fusobacterium necrophorum in primary endodontic infections from a Brazilian population and their antimicrobial susceptibility to some antibiotics by the E-test. One hundred ten samples from infected teeth with periapical pathologies were analyzed by culture methods. Five hundred eighty individual strains were isolated; 81.4% were strict anaerobes. F. nucleatum was found in 38 root canals and was associated with Porphyromonas gingivalis, Prevotella spp., and Eubacterium spp. F. necrophorum was found in 20 root canals and was associated with Peptostreptococcus prevotii. The simultaneous presence of F. nucleatum and F. necrophorum was not related to endodontic symptoms (p > 0.05). They were 100% susceptible to amoxicillin, amoxicillin/clavulanate, and cephaclor. Fusobacterium spp. is frequently isolated from primary-infected root canals of teeth with periapical pathologies. Amoxicillin is a useful antibiotic against F. nucleatum and F. necrophorum in endodontic infections and has been prescribed as the first choice in Brazil.


Assuntos
Doenças da Polpa Dentária/microbiologia , Infecções por Fusobacterium/microbiologia , Fusobacterium necrophorum/isolamento & purificação , Fusobacterium nucleatum/isolamento & purificação , Adolescente , Adulto , Amoxicilina/uso terapêutico , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Anaerobiose , Antibacterianos/uso terapêutico , Bifidobacterium/isolamento & purificação , Brasil , Cefaclor/uso terapêutico , Criança , Fístula Dentária/microbiologia , Cavidade Pulpar/microbiologia , Eubacterium/isolamento & purificação , Fusobacterium necrophorum/efeitos dos fármacos , Fusobacterium necrophorum/fisiologia , Fusobacterium nucleatum/efeitos dos fármacos , Fusobacterium nucleatum/fisiologia , Humanos , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Penicilina G/uso terapêutico , Peptostreptococcus/isolamento & purificação , Abscesso Periapical/microbiologia , Porphyromonas gingivalis/isolamento & purificação , Prevotella/isolamento & purificação , Staphylococcaceae/isolamento & purificação , Adulto Jovem
17.
Eur J Clin Microbiol Infect Dis ; 15(8): 646-9, 1996 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8894572

RESUMO

This study was undertaken to investigate the effects of prophylactic administration of cefaclor on bacteremia after dental extraction. Thirty-nine patients were randomly assigned to receive either 1 g cefaclor (19 patients) or placebo (20 patients) 1 h prior to dental extraction. Blood samples for microbiological investigation were collected before, during, and 10 min after surgery, and were processed by lysis filtration under anaerobic conditions. The incidence of bacteremia with viridans streptococci was 79% in the cefaclor group and 50% in the placebo group during extraction. No difference in the incidence or magnitude of bacteremia was observed when the two patient groups were compared.


Assuntos
Bacteriemia/prevenção & controle , Cefaclor/uso terapêutico , Cefalosporinas/uso terapêutico , Extração Dentária/efeitos adversos , Adulto , Idoso , Método Duplo-Cego , Feminino , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade
18.
J Prosthet Dent ; 77(4): 348-52, 1997 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9104709

RESUMO

PURPOSE: The aim of this study was to observe the antibacterial potential of polycarboxylate temporary cement containing a mixture of metronidazole, ciprofloxacin, and cefaclor on carious lesions of prepared abutments that were designed to leave caries on the abutments. MATERIAL AND METHODS: Antibacterial efficacy was estimated in vitro and in vivo by measuring bacterial recovery from the lesions. Bacteria counts ranged from 10(4) to 10(7) both in vitro (nine samples) and in vivo (five samples) in time-zero samples, just before the application of the antibacterial cement. RESULTS: No bacteria were recovered from carious lesions in vitro (six samples) or in vivo (four samples) after the lesions were covered by the antibacterial temporary cement. For the remaining samples, some bacteria (5 to 80 counts per sample) were recovered, with one notable exception in which marginal leakage provided a bacteria count of 10(3). Bacteria counts ranging from 10(3) to 10(5) occurred in carious lesions covered by temporary cement without antibacterial agents, which indicated that temporary cement alone was not a potent disinfectant. CONCLUSIONS: The results of this study indicated that the antibacterial temporary cement can be useful for eradicating bacteria from carious lesions of prepared abutments.


Assuntos
Antibacterianos/uso terapêutico , Bactérias/efeitos dos fármacos , Dente Suporte , Cárie Dentária/microbiologia , Restauração Dentária Temporária , Cimento de Policarboxilato/uso terapêutico , Preparo Prostodôntico do Dente , Adulto , Antibacterianos/química , Bactérias/crescimento & desenvolvimento , Cefaclor/uso terapêutico , Cefalosporinas/uso terapêutico , Ciprofloxacina/uso terapêutico , Contagem de Colônia Microbiana , Coroas , Cárie Dentária/terapia , Infiltração Dentária/microbiologia , Humanos , Metronidazol/uso terapêutico , Pessoa de Meia-Idade , Cimento de Policarboxilato/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA